findmyKOL
Clinical trialNCT02768805CompletedPhase 2Interventional

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

SponsorMedicagoEnrollment900RNA Virus InfectionsRespiratory Tract DiseasesRespiratory Tract InfectionsVirus Diseases
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies. The study is being conducted to demonstrate that the immunogenicity profile of the Quadrivalent VLP Vaccine meets the US Center for Biologics Evaluation and Research (CBER) licensure criteria. The study will also help to define the optimal dose, establish potential competitive advantages, and support the design of future studies.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • David Seiden, MD

    Broward Research Group (BRG), Hollywood (FL), USA

    Principal Investigator
    clinicaltrials.gov ↗
  • Deepen Patel, MD

    Topstone Research, Toronto, Canada

    Principal Investigator
    clinicaltrials.gov ↗
  • Diane Krieger, MD

    Miami Research Associates (MRA), Miami (FL), USA

    Principal Investigator
    clinicaltrials.gov ↗
  • Ginette Girard, MD

    Diex Research Sherbrooke, Sherbrooke, Canada

    Principal Investigator
    clinicaltrials.gov ↗
  • Marc Dionne, MD

    Équipe de recherche en vaccination du CHU de Québec-Université Laval (CHU), Quebec, Canada

    Principal Investigator
    clinicaltrials.gov ↗
  • Michael Libman, MD

    McGill University Health Center - Vaccine Study Center (MUHC), Montreal, Canada

    Principal Investigator
    clinicaltrials.gov ↗
  • Pierre Lachance, MD

    Centre de Recherche St-Louis, Quebec, Canada

    Principal Investigator
    clinicaltrials.gov ↗
  • Suchet R Patel, MD

    Regional Clinical Research (RCR), Endwell (NY), USA

    Principal Investigator
    clinicaltrials.gov ↗
  • Trevor Wesson, MD

    Diex Research Montreal, Montreal, Canada

    Principal Investigator
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Topstone Research

    Toronto, Ontario, Canada

  • Diex Research Montreal

    Montreal, Quebec, Canada

  • Mcgill University Health Center - Vaccine Study Center (muhc)

    Pierrefonds, Quebec, Canada

  • Diex Research Sherbroooke

    Sherbrooke, Quebec, Canada

  • Centre de Recherche St-Louis

    Québec, Canada

  • Équipe de Recherche En Vaccination Du Chu de Québec-Université Laval (chu)

    Québec, Canada

United States
  • Broward Research Group (brg)

    Hollywood, Florida, United States

  • Miami Research Associates (mra)

    South Miami, Florida, United States

  • Regional Clinical Research (rcr)

    Endwell, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

15 µg/strain of Quadrivalent VLP Vaccine15 µg/strain of the licensed quadrivalent vaccine30 µg/strain of Quadrivalent VLP Vaccine
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
2 Mar 2016
Primary completion
17 May 2016
Completion
26 Nov 2016
Last update posted
11 Jun 2020
Registered enrollment
900
Registry id
NCT02768805
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.